vimarsana.com
Home
Live Updates
New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting : vimarsana.com
New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting
V-INITIATE trial demonstrates that early initiation with Leqvio, prior to guideline-recommended ezetimibe, for ASCVD patients unable to achieve LDL-C goal on...
Related Keywords
South Korea ,
China ,
Japan ,
Amsterdam ,
Noord Holland ,
Netherlands ,
United States ,
Switzerland ,
American ,
America ,
Swiss ,
Han ,
Michael Koren ,
Sloan Simpson ,
Prnewswire Novartis ,
Marlena Abdinoor ,
Jonathan Graham ,
Parag Mahanti ,
Coll Cardiol ,
Michael Meo ,
Linkedin ,
Novartis Pharmaceuticals Corp ,
World Health Organization ,
European Medicines Agency ,
European Society Of Cardiology Congress ,
World Heart Federation ,
Instagram ,
Novartis Pharmaceuticals Corporation ,
Journal Of The American College Cardiology ,
American College Of Cardiology Heart Association ,
American College Of Cardiology Congress ,
Health Promotion Series ,
Alnylam Pharmaceuticals ,
Facebook ,
American Heart Association ,
Clinical Research ,
Novartis ,
Public Health ,
National Medical Products Administration ,
Exchange Commission ,
Jacksonville Center ,
European Union ,
Annual Scientific Session ,
American College ,
Medical Director ,
Safety Information ,
Atherosclerotic Cardiovascular Disease ,
Cardiology Congress ,
European Society ,
Medical Products ,
American Heart ,
American Heart Association Task Force ,
Clinical Practice ,
World Heart ,
Published May ,
vimarsana.com © 2020. All Rights Reserved.